Hepatitis C News

In a recently published commentary, Chelsea Elwood, MD, from the University of British Columbia, and colleagues advised that Canadian guidelines should recommend universal screening for hepatitis C in pregnant women as they do for hepatitis B and HIV to reduce the risk for vertical transmission.

Although not currently licensed for patients undergoing dialysis for severe renal impairment, researchers found that treatment with Epclusa for hepatitis C was safe and effective in patients with end-stage renal disease.

The CDC released an educational web feature and other educational resources for Pride Month designed to increase the awareness of hepatitis A outbreaks among men who have sex with men that have occurred both in the United States as well as internationally. The resources also provide information about hepatitis vaccinations.

Patients who received interferon-based antiviral therapy for chronic hepatitis C had a significantly lower incidence rate of Parkinson’s disease compared with untreated patients, according to an analysis published in JAMA Neurology.

Gilead Sciences Canada awarded a series of HCV Micro-Elimination Grants to 11 organizations focused on identifying individuals with hepatitis C in high-risk hard-to-reach populations throughout Canada and linking them to care, according to a press release.

Researchers identified a common polymorphism and a rare variant combination in hepatitis C genotype 3 that are responsible for a reduced response to Sovaldi, according to a study published in Gastroenterology.

SAN DIEGO — Over the next four days, the gastroenterology community will convene in the San Diego Convention Center for Digestive Disease Week 2019, the specialty’s largest scientific conference.

VIENNA — In this exclusive video from the International Liver Congress 2019, Philippa Easterbrook, MD, senior scientist of the Global Hepatitis Program within the HIV Department at the WHO headquarters in Geneva, Switzerland, discusses a symposium focused on sharing “good practices and lessons learned” in the global viral hepatitis response.

The FDA approved Mavyret to treat all six genotypes of hepatitis C in pediatric patients aged 12 years to 17 years, according to a press release from the organization.

VIENNA — In this exclusive video from the International Liver Congress 2019, Philippa Easterbrook, MD, senior scientist of the Global Hepatitis Program within the HIV Department at the WHO headquarters in Geneva, Switzerland, discusses the future of direct-acting antiviral access for children and adolescents with hepatitis C.